MARKET WIREYahoo • 23h ago
EBay Leads Five Stocks Near Buy Points From Resilient SectorsEbay, Quest Diagnostics, Fastenal, Chubb trade in or around buy points after earnings. TG Therapeutics breaks out.
Why DGX Stock surged +2.97% Today — RQD Quant Desk Flash
$252.92 +2.97% NYSE • Public Delayed / 60s Snapshot
Quest Diagnostics Incorporated (DGX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C+ • HOLD / WATCH
Cap $27.83B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+4% Base Target
WHALE OPTIONS TUG-OF-WAR:56% Call Buyers ($2.8M)
44% PutsMax Pain: $248.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DGX Stock surged +2.97% Today — RQD Quant Desk Flash
Quest Diagnostics Incorporated (DGX) surged +2.97% to $252.92 as options desks priced 56% call premium vs. 44% put protection around the $248 max-pain magnet. Solid 33% profit margin (10% return on capital), mixed timing at 28x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 95% of its 52-week range ($171.18 – $256.99) with RSI-14 at 68.3 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.8M in bullish call flow vs. $2.2M in put flow (Put/Call 0.78x, implied earnings swing ±6.9%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 33.2% gross margin and $1.4B annual free cash flow.
Live DGX Headlines & Catalysts
RISK WATCHYahoo • 1d ago
Labcorp, Quest urge RESULTS Act passage as lab payment cuts loomThe testing service providers hope the legislation, which would reform the CMS’ reimbursement rate-setting process, can cross the finish line in Congress’ lame-duck session.
MARKET WIREYahoo • 1d ago
Global Genetic Counseling Services Market Report 2026 | Capitalize on AI and Telehealth as Market Hits $4.67 Billion by 2030: Labcorp, Quest Diagnostics, Natera, GeneDxPlayers: Labcorp, Quest Diagnostics, Eurofins Scientific, Exact Sciences and Revvity. The report profiles competitors, regional shares, segments, trends and opportunities.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Geneti
MARKET WIREYahoo • 1d ago
Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and IlluminaPlayers: Thermo Fisher, Labcorp, Quest Diagnostics, Eurofins, Agilent. Profiles cover fetal aneuploidy tests, technologies, applications and end users.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Fetal Aneuploidy Confirmat
CATALYSTSeekingAlpha • 2d ago
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take ShareBillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy.
RISK WATCHYahoo • 3d ago
Can Hims & Hers Stock Fall 30%?For questions about this article or underlying research, email help@trefis.com.
CATALYSTYahoo • 4d ago
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
MARKET WIRESeekingAlpha • 5d ago
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio UpdateCATALYSTSeekingAlpha • 5d ago
Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer'sCATALYSTYahoo • 8d ago
Quest Diagnostics (DGX) Stock Price Stalls After Strong Q3 EarningsQuest Diagnostics just posted Q3 2026 results that looked firm on paper while the stock barely flinched. Shares sit at about US$241.89, down 0.6% today and only modestly higher over the past month, even as revenue for th
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live DGX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
DGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.67%⚡ TESTING RESISTANCE
2026-10-30O $255.1H $257.0L $251.0C $251.8VOL 919.6K
RES: $255.5SUP: $226.0SMA50: $238.5SMA200: $212.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
21.5%/yr Implied 5Y Growth
vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DGX stock moving today?
Why DGX Stock surged +2.97% Today — RQD Quant Desk Flash. Solid 33% profit margin (10% return on capital), mixed timing at 28x P/E—hold if owned, no rush to chase.